Keywords: Lp (a); AJ; adherent junction; ApoA1; apoprotein-A1; Apo-B; apoprotein-B; BBB; blood-brain barrier; Chol; Cholesterol; CI; confidence interval; DM; diabetes mellitus; DWM; deep white matter; HbA1C; glycated haemoglobin; tHcy; total homocyeteine; HDL; high density
مقالات ISI Lp (a) (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Lp (a); Antisense oligonucleotides; PCSK9 inhibitors; Apolipoprotein CIII inhibitors; CETP inhibitors; Lp(a);
Keywords: Lp (a); 25(OH)D; 25-hydroxyvitamin D; AITT; arginine insulin tolerance test; Apo; apolipoprotein; AITT; arginine-insulin tolerance test; BMI; body mass index; BMC; bone mineral content; BMCapp; bone mineral content appendicular; BMCHA; bone mineral content height
Keywords: Lp (a); FH; Early treatment; LDL-apheresis; Lp(a);
Keywords: Lp (a); Lp(a); lipoprotein(a); LDL; low-density lipoprotein; apoB100; apolipoprotein B100; apo(a); apolipoprotein(a); CVD; cardiovascular disease; LDL-C; LDL-cholesterol; HDL-C; high-density lipoprotein cholesterol; K; kringle; PCSK9; proprotein covertase subtili
Keywords: Lp (a); Lipid apheresis; Lipoprotein apheresis; Dyslipidemia; Liposorber; Whole blood system; Plasma system; DSA; dextran sulfate adsorption; FH; familial hypercholesterolemia; HELP; heparin-induced extracorporeal LDL precipitation; LDL-C; LDL-cholesterol; Lp(a);
Keywords: Lp (a); Lipid emulsion; Parenteral nutrition; Fatty acids; Lipid profile; Oxidative stress; ALA; α-linolenic acid; ApoaI; apolipoprotein aI; Apob; apolipoprotein b; ARA; arachidonic acid; BUN; blood urea nitrogen; Cr; creatinine; DHA; docosahexaenoic acid; EN; e
Keywords: Lp (a); Lipoprotein apheresis; Familial hypercholesterolemia; LDL-C; CVD; Atherosclerosis; Lp(a);
Keywords: Lp (a); AACE; American Association of Clinical Endocrinologists; ACC; American College of Cardiology; ACE; Africa Middle East Cardiovascular Epidemiological; AHA; American Heart Association; ASCVD; atherosclerotic cardiovascular disease; BMI; body mass index; CAD
Keywords: Lp (a); ACC/AHA; American College of Cardiology/American Heart Association; ApoB; apolipoprotein B; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; DLCN; Dutch Lipid Clinic Network; FAMCAT; an FH prediction model; FDA; Food and Drug Ad
Keywords: Lp (a); ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CVD; cardiovascular disease; CYP; cytochrome; EAS; European Atherosclerosis Society; FDA; Food and Drug Administration; FH; Familial hypercholesterolemia; GOF; gain of function; H
Keywords: Lp (a); Lipoprotein apheresis; Familial hypercholesterolemia; LDL-C; CVD; Atherosclerosis; Lp(a);
Keywords: Lp (a); CAD; coronary artery disease; CVD; cardiovascular disease; TC; total cholesterol; HDL-C; high-density lipoprotein cholesterol; LDL-C; low density lipoprotein cholesterol; TG; triglycerides; ApoAI; apolipoprotein AI; ApoB; apolipoprotein B; Lp(a); lipoprot
Keywords: Lp (a); CAD; coronary artery disease; WBC; white blood cell; TC; total cholesterol; TG; triglycerides; LDL-C; low-density lipoprotein cholesterol; HDL-C; high-density lipoprotein cholesterol; Lp(a); lipoprotein(a); hsCRP; high sensitivity C-reactive protein; Walk
Keywords: Lp (a); ALP; alkaline phosphatase; BPdias; diastolic blood pressure; BPsys; systolic blood pressure; cAMP; adenosine 3â²,5â²-cyclic monophosphate; cGMP; guanosine 3â²,5â²-cyclic monophosphate; CREA; creatinine; CS; chondroitin sulfate; GPx; glutathione peroxi
Keywords: Lp (a); ALT; alanine aminotransferase; ApoAI; apolipoprotein AI resp. ApoAII, ApoCII, ApoCIII; AST; aspartate aminotransferase; CRP; C-reactive protein; DGLA; dihomo-gamma-linolenic acid; FFA; free fatty acid; GGT; gamma glutamyltransferase; IL-6; interleukin-6;
Keywords: Lp (a); ABI; ankle-brachial index; ACC; American College of Cardiology; AHA; American Heart Association; aPWV; aortic pulse wave velocity; ASCVD; atherosclerotic cardiovascular disease; ATP-III; Adult Treatment Panel III; CAC; coronary artery calcium; CCA; common
Keywords: Lp (a); AAV1; adeno-associated virus serotype 1; ACC; American College of Cardiology; ACCELERATE; A Study of Evacetrapib in High-Risk Vascular Disease; ACCORD; Action to Control Cardiovascular Risk in Diabetes; ADA; American Diabetes Association; AMP; adenosine m
Keywords: Lp (a); APO(a); apolipoprotein(a); DH; DNase hypersensitivity; ERE; estrogen-response element; Lp(a); lipoptrotein(a); PLG; plasminogen; TSS; transcription start site; Plasminogen; Estrogen; Estrogen receptor; Enhancer element; Promoter; Transcription;
Maturity Onset Diabetes of the Young (MODY) in Tunisia: Low frequencies of GCK and HNF1A mutations
Keywords: Lp (a); Apo A; apolipoprotein A; Apo B; apolipoprotein B; BMI; body mass index; DHPLC; Denaturing High Performance Liquid Chromatography; GAD; Anti-Glutamic acid Decarboxylase; HbA1c; glycated hemoglobin; HDL-C; high-density lipoprotein cholesterol; HLA-DRB1; HLA
Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children
Keywords: Lp (a); Familial hypercholesterolemia; Children; IDOL; LDLR; PCSK9; LDL; 2D-1H-NMR; Lp(a); Triglyceride;
Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease
Keywords: Lp (a); Lipoprotein (a); Recurrent cardiovascular outcomes; Secondary prevention; Lp(a); Lipoprotein (a); CAD; coronary artery disease; CVD; cerebrovascular disease; PAD; peripheral artery disease;
Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A caseâcontrol study
Keywords: Lp (a); FH; familial hypercholesterolemia; LDLR; low-density lipoprotein receptor; APOB; apolipoprotein B; PCSK9; proprotein convertase subtilisin/kexin type 9; LDL-C; low-density lipoprotein cholesterol; Lp(a); lipoprotein (a); ASCVD; atherosclerotic cardiovascu
Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis
Keywords: Lp (a); Atherosclerosis; Postprandial remnant lipoproteins; Very low density lipoproteins (VLDL) (remnants); Chylomicrons (remnants); Lipoprotein lipase (LPL); Hepatic triglyceride lipase (HTGL); Lp(a); Chylomicronemia;
The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis
Keywords: Lp (a); ACAT; Acyl-CoA:cholesterol acyltransferase; ADAM17; a disintegrin and metalloproteinase 17; APO; apolipoprotein; COL18; collagen XVIII; CS/DS; chondroitin sulfate/dermatan sulfate; FLOT1; flotilin-1; GLCE; C5 epimerase; GPIHBP1; glycosylphosphatidylinosit
Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial
Keywords: Lp (a); Alirocumab; Diabetes; Insulin; LDL-C; ODYSSEY; PCSK9; AE; adverse event; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CV; cardiovascular; CVD; cardiovascular disease; DM; diabetes mellitus; HDL-C; high-d
Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE
Keywords: Lp (a); Familial hypercholesterolemia; Cardiovascular disease; Risk stratification; Smoking; Hypertension; Gender; Age; HDL-C; Lp(a);
Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention
Keywords: Lp (a); Lipoprotein(a); Lp(a); Lipids; Cholesterol; Coronary heart disease; Prevention; Cardiovascular risk; Residual cardiovascular risk;
Lipoprotein apheresis influences monocyte subpopulations
Keywords: Lp (a); Lipoprotein apheresis; Monocytes; Subpopulations; BMI; body mass index; CHD; coronary heart disease; PAOD; peripheral arterial occlusive disease; MI; myocardial infarction; TC; total cholesterol; LDL-C; low-density lipoprotein cholesterol; HDL-C; high-den
Efficacy of lipid reduction with DALI and MONET
Keywords: Lp (a); DALI; MONET; Lipids; Lipidapheresis; Hypercholesterolemia; Lp(a); Cholesterol;
Accelerated atherosclerosis and elevated lipoprotein (a) after liver transplantation
Keywords: Lp (a); Lp(a); Lipids; Prevention; Cardiovascular disease; Therapy;
PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia
Keywords: Lp (a); Coronary artery calcification; Lipids and lipoprotein metabolism; Hypercholesterolemia; PCSK9; proprotein convertase subtilisin kexin type 9; LDL-C; low-density lipoprotein cholesterol; LDLR; low-density lipoprotein receptor; LLT; lipid lowering therapy;
Homocisteína plasmática, Lp(a) y marcadores de estrés oxidativo en la vasculopatía periférica del paciente con diabetes tipo 2
Keywords: Lp (a); Diabetes tipo 2; Vasculopatía periférica; Índice tobillo-brazo; Homocisteína; Lp(a); Sistema glutatión; Estrés oxidativoType 2 diabetes; Peripheral macroangiopathy; Ankle brachial index; Homocysteine; Lp(a); Glutathione system; Oxidative stress
JCL Roundtable: Should we treat elevations in Lp(a)?
Keywords: Lp (a); Lp(a); Lipoprotein; Vascular disease; LDL-Cholesterol; Pharmacotherapy;
Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a)
Keywords: Lp (a); apo; apolipoprotein; CHD; coronary heart disease; d; density; FCR; fractional catabolic rate; GC/MS; gas chromatography/mass spectrometry; IDL; intermediate density lipoprotein (d 1.006-1.019Â g/mL); KIV1; kringle IV1; KIV2; kringle IV2; Lp(a); lipoprot
The re-emergence of lipoprotein(a) in a broader clinical arena
Keywords: Lp (a); apo; apolipoprotein; AS; aortic stenosis; CAVS; calcific aortic valve stenosis; CVD; cardiovascular disease; LDL; low-density lipoprotein; LDL-C; low-density lipoprotein cholesterol; Lp(a); lipoprotein(a); OMT; optimal medical therapy; OxPL; oxidized phos
Clinical peptide and protein quantification by mass spectrometry (MS)
Keywords: Lp (a); Peptide; Protein; Quantitation; Clinical; Laboratory-testing; Mass spectrometry; Immunoassay limitations; Isoforms; Fragments; Assay-harmonization; 25-OH-D; 25-hydroxy Vitamin D; AA; African American; AIC; analyte immunocapture; aa; Amino acid(s); AngI; a
Validation of a lipoprotein(a) particle concentration assay by quantitative lipoprotein immunofixation electrophoresis
Keywords: Lp (a); P; particle concentration; CVD; cardiovascular disease; Lp(a); lipoprotein(a); Lipo-IFE; lipoprotein immunofixation electrophoresis; K; kringle; SPIFE; serum protein immunofixation electrophoresis; IDL; intermediate density lipoprotein; Lipoprotein(a); Li
High Lipoprotein(a) Concentrations Are Associated with Impaired Endothelial Function in Children
Keywords: Lp (a); FH; Familial hypercholesterolemia; FMD; Flow-mediated dilation; LDL; Low-density lipoprotein; Lp(a); Lipoprotein(a);
Molecular characterization of p.Asp77Gly and the novel p.Ala163Val and p.Ala163Glu mutations causing protein C deficiency
Keywords: Lp (a); PC; Protein C; APC; Activated protein C; FVa; activated factor V; FVIIIa; activated factor VIII; PS; protein S; FV; native factor V; PROC; gene for human PC; Gla; gamma-carboxyglutamic acid; EGF; epidermal growth factor; SP; serine protease; VTE; venous t
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy: The TNT Trial
Keywords: Lp (a); atherosclerosis; biomarker; coronary heart disease; inflammatory; oxidation-specific epitope; apoB; apolipoprotein B-100; CHD; coronary heart disease; LDL-C; low-density lipoprotein cholesterol; Lp(a); lipoprotein(a); MACE; major adverse cardiac event(s);
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Keywords: Lp (a); Proprotein convertase subtilisin/kexin type 9; Type 2 diabetes mellitus; LDL-receptor; Lp(a); Dyslipidemia;
Laboratory validation of a low density lipoprotein apolipoprotein-B assay
Keywords: Lp (a); Apo-B; apolipoprotein B; LDL; low density lipoprotein; LDL-C; low density lipoprotein cholesterol; LDL-P; low density lipoprotein particle number; VLDL; very low density lipoprotein; IDL; intermediate density lipoprotein; Lp(a); lipoprotein (a); CHD; coro
Lipoprotein (a), LPA Ile4399Met, and Fibrin Clot Properties
Keywords: Lp (a); Lp(a); lipoprotein(a); apo(a); apolipoprotein(a); SNP; single nucleotide polymorphism; Lipoprotein(a); fibrin clot; polymorphism; genetics; thrombosis;
The influence of apolipoprotein A5 T-1131C and apolipoprotein E common genetic variants on the levels of hemostatic markers in dyslipidemic patients
Keywords: Lp (a); MetS; metabolic syndrome; NCEP; National Cholesterol Education Program; ATP; adult treatment panel; SBP; systolic blood pressure; DBP; diastolic blood pressure; BMI; body mass index; CRP; C-reactive protein; TC; total cholesterol; TG; triglycerides; HDLc;
Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype
Keywords: Lp (a); Lp(a); Lipoprotein(a); Apo(a); Apolipoprotein(a); LDL; Low density lipoprotein; LPA; apolipoprotein(a) gene; NA; Nicotinic acid; HDL; High density lipoprotein; PCR; Polymerase Chain Reaction; BMI; Body Mass Index; HOMA-IR; Homeostasis Model of Assessment-
Genetic variants of apolipoprotein A5 T-1131C and apolipoprotein E common polymorphisms and their relationship to features of metabolic syndrome in adult dyslipidemic patients
Keywords: Lp (a); MetS; metabolic syndrome; NCEP; National Cholesterol Education Program; ATP; Adult Treatment Panel; SBP; systolic blood pressure; DBP; diastolic blood pressure; BMI; body mass index; CRP; C-reactive protein; TC; total cholesterol; TG; triglycerides; HDLc;
Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice
Keywords: Lp (a); CVD; GSH; GPx; Ribose-cysteine; Oxidised lipids; LDL; apoB; CVD; cardiovascular disease; Lp(a); lipoprotein(a); LDL; low density lipoprotein; HDL; high density lipoprotein; TG; triglycerides; apoB; apolipoproteinB-100; GSH; glutathione; GPx; glutathione p
Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab
Keywords: Lp (a); evolocumab; dyslipidemia; monotherapy; PCSK9Â inhibition; AE; adverse event(s); CV; cardiovascular; HDL-C; high-density lipoprotein cholesterol; LDL-C; low-density lipoprotein cholesterol; Lp(a); lipoprotein; PCSK9; proprotein convertase subtilisin/kexin
Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia
Keywords: Lp (a); apo; apolipoprotein; CE; cholesteryl esters; CHD; coronary heart disease; FH; familial hypercholesterolemia; HDL-C; high-density lipoprotein-cholesterol; LCAT; lecithin-cholesterol-acyl-transferase; LDL-C; low-density lipoprotein-cholesterol; Lp(a); lipop